HDAC9 and neoplasm: In addition, combination treatment with GSK126 (a methyltransferase inhibitor) and LB201 (a class 1/2 HDAC inhibitor) enhances expression of CXCL9 and 10 in brain tumor cell lines, resulting in increased T cell trafficking toward tumor cells.